1. Home
  2. >News
  3. >Helix Obtains Fda Authorization For Exome Sequencing Platform Alzheimer S Disease Risk Test
Skip to main content
News

Helix Obtains FDA Authorization for Exome Sequencing Platform, Alzheimer's Disease Risk Test

January 11, 2021Company News

Ready to see the whole picture?

Connect with our team to discover how Helix can transform your approach to genomic medicine.